abstract |
The present invention relates to truncated GIP analogs which comprise one or more substitutions compared to wild-type GIP and which may have altered, preferably increased, GIP activity properties, such as, for example, in an in vitro efficacy assay. Evaluation. The present invention provides GIP-GLP-1 dual agonist compounds and related methods. |